Amgen Launches Preemptive Strike in Patent Battle

Law360, New York (April 24, 2006, 12:00 AM EDT) -- In an effort to fend off future claims of patent infringement relating to two of its anti-arthritis drugs, Amgen Inc. has filed a lawsuit in a federal court in Delaware seeking declaratory judgment.

Amgen’s complaint against rival drug company Ariad Pharmaceuticals Inc., which was filed Thursday, implies that future patent infringement claims against Amgen’s drugs Enbrel and Kineret are a virtual certainty. Those claims would stem from Ariad’s patent—U.S. Patent no. 6,410,516—which covers the regulation of NF-(kappa)B cell-signaling activity as a treatment for disease.

“Ariad’s actions...
To view the full article, register now.

Law360 UK

UK Financial Services

Read Our Latest UK Legal News & Analysis

Financial Services Law360 UK and Insurance Law360 UK provide breaking news and in-depth analysis on U.K. and European Union regulation, enforcement, legislation, and litigation involving banks, investment firms, insurers, and more.